Tegmine Therapeutics

What We Do

At Tegmine we target glycoproteins, which are a hallmark of numerous solid cancers and drive aggressive disease. We’ve engineered a system to generate revolutionary new antibody-based therapies for cancer which dramatically increase efficacy while reducing toxic side effects. Our proprietary TegMiner™ platform enables the discovery of unique cancer epitopes and allows us to develop these life-changing new antibodies for patients with unmet needs.

Jeff Bernstein, PhD - CEO

PhD Biomedical Engineering, UCLA
17+ years Pharma / Biotech experience: Merck, Stemcentrx
1 approved drug - V114 (glycoconjugate vaccine)
8+ years experience in developing pre-clinical stage cancer drug leads
5+ years experience in process development for clinical stage therapeutics

Join Us in Redefining Precision Oncology

What We Offer

Purpose-Driven Work – Every experiment, every meeting, every breakthrough matters because it brings us closer to eradicating cancer.

A Culture of Innovation – We empower bold ideas and embrace the unexpected discoveries that move science forward.

Room to Grow – From scientific roles to operational leadership, Tegmine is a place where careers can evolve as quickly as our pipeline.

Collaboration at Our Core – We believe the best solutions come from diverse perspectives and open exchange—across teams, disciplines, and partners.

We’re looking for passionate scientists, innovators, and problem-solvers who want to do more than just work—they want to make an impact. Ready to help us engineer the next generation of cancer therapies?

Get in Touch

Corporate Address
4104 24th St., Suite PMB 405
San Francisco, CA 94114
USA
Email
operations@tegminetx.com

Send Message

Research Center
329 Oyster Point Blvd., 3rd Floor
South San Francisco, CA 94080
USA
Social
- LinkedIn

News